Medicine and Dentistry
Radioimmunotherapy
100%
PARP Inhibitor
100%
Tositumomab
100%
Aggressive Lymphoma
100%
External Beam Radiotherapy
75%
Poly ADP Ribose Polymerase
75%
Confocal Microscopy
50%
Incubation
50%
Lymphoma Cell
50%
Green Fluorescent Protein
25%
Radiation Exposure
25%
Cell Viability
25%
Epstein Barr Virus
25%
Iodine 131
25%
Luciferase
25%
Radiosensitization
25%
Radiosensitizer
25%
Non-Hodgkin Lymphoma Cell Line
25%
Raji Cell
25%
Keyphrases
Radioimmunotherapy
100%
External Beam
100%
Aggressive Lymphoma
100%
PARP Inhibitor (PARPi)
100%
AZD2281
100%
ABT-888
75%
Tositumomab
33%
Lymphoma Cells
25%
External Beam Radiation
25%
Poly(ADP-ribose) Polymerase
25%
Confocal Microscopy
16%
Incubation
16%
Double-strand Breaks
16%
Radiosensitization
16%
Viable Cells
16%
Raji
16%
Relative Reduction
8%
Non-Hodgkin Lymphoma
8%
Radiation Exposure
8%
Radiation Dose
8%
Green Fluorescent Protein
8%
Cell Viability
8%
Epstein-Barr Virus
8%
Luciferase
8%
Growth Curve
8%
Radiation-protective Agents
8%
Raji Cells
8%
Activity Assay
8%
Log Phase
8%
Radiosensitizing Effect
8%
Phase Growth
8%
Assay Kit
8%
H2AX
8%
Polymerase Assay
8%
Pharmacology, Toxicology and Pharmaceutical Science
Tositumomab
100%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
100%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase
75%
Confocal Microscopy
50%
Nonhodgkin Lymphoma
25%
Epstein-Barr Virus
25%
Cell Viability
25%
Luciferase
25%
Iodine-131
25%
Radiation Exposure
25%
Radiosensitizing Agent
25%
Green Fluorescent Protein
25%
Immunology and Microbiology
Tositumomab
100%
Radiation Beam
75%
Lymphoma Cell
50%
Confocal Microscopy
50%
Cell Viability
25%
Radiosensitization
25%
Non-Hodgkin Lymphoma Cell Line
25%
Iodine-131
25%
Percentage of Viable Cells
25%
Epstein Barr Virus
25%